Author:
He Wen-Zhuo,Huang Yu-Hua,Hu Wan-Ming,Wang Fang,Xu Yu-Xia,Yi Jia-Hong,Xue Ju,Yang Yuan-Zhong,Chao Xiao-Ying,Lin Han-Bin,Guo Gui-Fang,Yun Jing-Ping,Xia Liang-Ping
Reference20 articles.
1. Current and emerging therapies for advanced biliary tract cancers;Kam;Lancet Gastroenterol Hepatol,2021
2. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study;Oh;Lancet Gastroenterol Hepatol,2022
3. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies;Piha-Paul;Int J Cancer,2020
4. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial;Kelley;Lancet,2023
5. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer;Oh;NEJM Evid,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献